# US 2026/0092098 A1 · Human a interferon receptor binding-related site mutant and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0092098 A1
- Document ID: US20260092098A1
- Status: Published application
- Kind: A1
- Application number: 19/133,302
- Filed: 2020-01-22
- Published: 2026-04-02
- Earliest claimed: 2019-01-30
- Assignees: Fudan University
- Applicants: Fudan University
- Inventors: Zhenghong YUAN; Jieliang CHEN; Yaming LI
- Web page: https://patentgrep.com/patent/US20260092098A1

## CPC

- C07K 14/7156: {for interferons [IFN]}
- A61K 38/21: Interferons {[IFN]}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/20: for DNA viruses
- C07K 14/56: IFN-alpha
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided is a human a interferon receptor binding-related site mutant IFN-α2-EIFK. The mutant has stronger anti-hepatitis B virus activity than IFN-α2, and has no cytotoxic effect at an antiviral concentration. An anti-hepatitis B virus drug can be prepared therefrom.

## Claims

### Claim 1

A human interferon alpha receptor 2 (IFN-α2) mutant, comprising the amino acid sequence of SEQ ID NO: 1 with one or more substitutions selected from D82E, T86I, Y89F, and R120K.

### Claim 2 (depends on 1)

A method for treating hepatitis B virus infection in a subject comprising administrating the human IFN-α2 mutant according to claim 1 to the subject.

### Claim 3 (depends on 1)

A method for reducing the level of hepatitis B surface antigen (HBsAg), hepatitis B e-antigen (HBeAg), and/or viral genomic DNA of hepatitis B virus in a subject with hepatitis B virus infection, comprising administrating the human IFN-α2 mutant according to claim 1 to the subject.

### Claim 4 (depends on 1)

A method for inhibiting the production of HBsAg, HBeAg, and/or viral DNA of hepatitis B virus in hepatocytes infected with hepatitis B virus, comprising administrating the human IFN-α2 mutant according to claim 1 to the hepatocytes.

### Claim 5 (depends on 1)

The human IFN-α2 according to claim 1, wherein at the same working concentration, the anti-hepatitis B virus activity of the IFN-α2 mutant is higher than that of IFN-α2.

### Claim 6 (depends on 4)

The method according to claim 4, comprising activating the JAK-STAT1/STAT2 pathway and the Interferon-Stimulated Response Element (ISRE), and inducing a high level of an antiviral molecule.

### Claim 7 (depends on 1)

The human IFN-α2 mutant according to claim 1, wherein the IFN-α2 mutant comprises the substitutions of D82E, T86I, Y89F, and R120K.

### Claim 8 (depends on 1)

The human IFN-α2 mutant according to claim 1, wherein the IFN-α2 mutant comprises the amino acid sequence set forth in SEQ ID NO: 2.

### Claim 9 (depends on 1)

The human IFN-α2 mutant according to claim 1, wherein the effective concentration of the IFN-α2 mutant to achieve an antiviral effect is 10-fold less than that of wild-type IFN-α2.

### Claim 10 (depends on 2)

The method according to claim 2, wherein the hepatitis B virus infection is chronic hepatitis B virus infection.

### Claim 11 (depends on 6)

The method according to claim 6, wherein the antiviral molecule is Interferon-Stimulated Genes (ISGs).
